Why Liquidia's Stock Is Trading Higher Today

Liquidia LQDA shares are trading higher on Monday. The company said that on Oct. 16 it had received an unsolicited offer to enter into a License Agreement for the LIQ861 and has postponed its special meeting in order to fully consider the offer.

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain.

Liquidia shares traded up 17.83% to $3.37 on Monday. The stock has a 52-week high of $12.10 and a 52-week low of $2.65.